Who is sponsoring NCT00740129?

NCT00740129 is sponsored by Novartis Pharmaceuticals.

What condition does NCT00740129 study?

NCT00740129 studies Paget's Disease of the Bone.

What drugs are being tested in NCT00740129?

Interventions: Zoledronic Acid.

What is the status of NCT00740129?

NCT00740129 is currently COMPLETED.

Last reviewed 2021-05-26 · How we verify

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

NCT00740129 PHASE4 COMPLETED Results posted

The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE4
Status	COMPLETED
Enrolment	6
Start date	Tue Oct 21 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 14 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Paget's Disease of the Bone

Interventions

Zoledronic Acid

Countries

New Zealand, South Africa, Belgium, United Kingdom, Canada, Spain